Targovax develops immuno-oncology therapies targeting solid tumors, and its market cap now stands at NOK 957.5M (€102.5M). The company’s candidate, TG01, is under development to treat pancreatic cancer, one of the most deadly forms of the disease. Only 7-25% of early-stage patients survive 5 years, and median survival falls as low as 2-6 months in late-stage patients.
The results of a Phase I/II study saw all 13 patients in a reduced-dosage cohort survive for 1 year following surgery. The trial will continue to see if the drug’s efficacy can be maintained for another year. Read more . . .